Hans-Guido Wendel

Dr. Wendel is a Principal Investigator at the Cancer Genetics Laboratory at Memorial Sloan-Kettering Cancer Center. He trained in medicine in Aachen and Edinburgh and currently holds Associate Member status at the Sloan-Kettering Institute. His research focuses on identifying novel cancer therapies through genetic analysis, with particular emphasis on lymphatic leukemias and lymphomas. He has identified translation -- the process converting messenger RNA into proteins -- as an understudied area in cancer research. His laboratory investigates natural compounds from plants, marine sponges, and corals that target translation processes, seeking to understand their potential clinical applications in cancer treatment.

• RNA G-quadruplexes Cause eIF4A-Dependent Oncogene Translation in Cancer (2014) Paper
• Loss of the HVEM Tumor Suppressor in Lymphoma and Restoration by Modified CAR-T Cells (2016) Paper
• CREBBP Inactivation Promotes the Development of HDAC3-Dependent Lymphomas (2017) Paper
• The Oncogenic Action of NRF2 Depends on De-glycation by Fructosamine-3-Kinase (2016) Paper